Recovery from heart failure with circulatory assist: A working group of the national, heart, lung, and blood institute

被引:16
|
作者
Reinlib, L
Abraham, W
机构
[1] US Dept HHS, NHLBI, Div Heart & Vasc Dis, NIH, Bethesda, MD USA
[2] Ohio State Univ, Div Cardiol, Columbus, OH 43210 USA
关键词
heart failure; LVAD; circulatory assist; devices; mechanical circulatory support;
D O I
10.1016/S1071-9164(03)00592-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Over the past decade, mechanical circulatory support has been beneficial as a bridge to cardiac transplantation, and anecdotal evidence suggests that heart failure patients fitted with mechanical assist devices experience direct cardiac benefits. Moreover, recent trials on limited numbers and subpopulations of patients-notably the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH)-support earlier observations of improved cardiac function and point towards the use of assist devices as destination therapy. Methods and Results: To investigate this phenomenon, on August 2-3, 2001, the National Heart, Lung, and Blood Institute convened the working group, "Recovery from Heart Failure with Circulatory Assist" in Bethesda, Maryland. The team included cardiac surgeons, cardiologists, and experts in experimental research. The goal was to prioritize recommendations to guide future programs in: (1) elucidating the mechanisms leading to reverse remodeling associated with a left ventricular assist device (LVAD); (2) exploring advanced treatments, including novel pharmacologies, tissue engineering, and cell therapies, to optimize recovery with LVAD therapy; and (3) identifying target genes, proteins, and cellular pathways to focus on for production of novel therapies for myocardial recovery and cardiovascular disease. Conclusions: The working group also made research and clinical recommendations to eventually translate findings into improved therapeutic strategies and device design: (1) support collaborations among clinical and basic scientists with an emphasis on clinical/translational research that might eventually lead to clinical trials; (2) identify candidate patients most likely to benefit from LVAD as a destination therapy; (3) explore potential biomarkers indicating when patients could most successfully be weaned from devices; and (4) promote clinical and experimental study of mechanically assisted organs and the tissue derived from them.
引用
收藏
页码:459 / 463
页数:5
相关论文
共 50 条
  • [1] Advancing the Science of Myocardial Recovery With Mechanical Circulatory Support: A Working Group of the National, Heart, Lung and Blood Institute
    Drakos, Stavros G.
    Pagani, Francis D.
    Lundberg, Martha S.
    Baldwin, J. Timothy
    JOURNAL OF CARDIAC FAILURE, 2017, 23 (05) : 416 - 421
  • [2] Advancing the Science of Myocardial Recovery with Mechanical Circulatory Support: A Working Group of the National, Heart, Lung, and Blood Institute
    Drakos, Stavros G.
    Pagani, Francis D.
    Lundberg, Martha S.
    Baldwin, J. Timothy
    ASAIO JOURNAL, 2017, 63 (04) : 445 - 449
  • [3] Advancing the science of myocardial recovery with mechanical circulatory support: A Working Group of the National, Heart, Lung, and Blood Institute
    Drakos, Stavros G.
    Pagani, Francis D.
    Lundberg, Martha S.
    Baldwin, Timothy J.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2017, 154 (01): : 165 - 170
  • [4] Recommendations of the National Heart, Lung and Blood Institute Heart and Lung Tolerance Working Group
    Massicot-Fisher, J
    Noel, P
    Madsen, JC
    TRANSPLANTATION, 2001, 72 (08) : 1467 - 1470
  • [5] Recommendations of the National Heart, Lung, and Blood Institute Heart and Lung Xenotransplantation Working Group
    Platt, J
    DiSesa, V
    Gail, D
    Massicot-Fisher, J
    CIRCULATION, 2002, 106 (09) : 1043 - 1047
  • [6] New Mechanistic and Therapeutic Targets for Pediatric Heart Failure Report From a National Heart, Lung, and Blood Institute Working Group
    Burns, Kristin M.
    Byrne, Barry J.
    Gelb, Bruce D.
    Kuehn, Bernhard
    Leinwand, Leslie A.
    Mital, Seema
    Pearson, Gail D.
    Rodefeld, Mark
    Rossano, Joseph W.
    Stauffer, Brian L.
    Taylor, Michael D.
    Towbin, Jeffrey A.
    Redington, Andrew N.
    CIRCULATION, 2014, 130 (01) : 79 - 86
  • [7] Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group
    Buxton, DB
    Lee, SC
    Wickline, SA
    Ferrari, M
    CIRCULATION, 2003, 108 (22) : 2737 - 2742
  • [8] Research Priorities for Heart Failure With Preserved Ejection Fraction National Heart, Lung, and Blood Institute Working Group Summary
    Shah, Sanjiv J.
    Borlaug, Barry A.
    Kitzman, Dalane W.
    McCulloch, Andrew D.
    Blaxall, Burns C.
    Agarwal, Rajiv
    Chirinos, Julio A.
    Collins, Sheila
    Deo, Rahul C.
    Gladwin, Mark T.
    Granzier, Henk
    Hummel, Scott L.
    Kass, David A.
    Redfield, Margaret M.
    Sam, Flora
    Wang, Thomas J.
    Desvigne-Nickens, Patrice
    Adhikari, Bishow B.
    CIRCULATION, 2020, 141 (12) : 1001 - 1026
  • [9] Report of the National Heart, Lung, and Blood Institute Working Group on Epigenetics and Hypertension
    Cowley, Allen W., Jr.
    Nadeau, Joseph H.
    Baccarelli, Andrea
    Berecek, Kathleen
    Fornage, Myriam
    Gibbons, Gary H.
    Harrison, David G.
    Liang, Mingyu
    Nathanielsz, Peter W.
    O'Connor, Daniel T.
    Ordovas, Jose
    Peng, Weiqun
    Soares, Marcelo Bento
    Szyf, Moshe
    Tolunay, H. Eser
    Wood, Katherine C.
    Zhao, Keji
    Galis, Zorina S.
    HYPERTENSION, 2012, 59 (05) : 899 - 905
  • [10] National Heart, Lung, and Blood Institute Clinical Proteomics Working Group report
    Granger, CB
    Van Eyk, JE
    Mockrin, SC
    Anderson, NL
    CIRCULATION, 2004, 109 (14) : 1697 - 1703